Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes

Other illness

• Patients:
  • Myeloid disease other than MDS (including chronic myelomonocytic leukemia and MDS/SMP) ;
  • Ongoing treatments for MDS (excluding erythropoietin, granulocyte colony-stimulating factor and transfusions) ;
  • Medical conditions that may interfere with immune system testing: active cancer, active autoimmune disease, inflammatory conditions, immunosuppressive therapy. ; \* Pregnant or breastfeeding women ; Patient's refusal ;
  • Person benefiting from a system of protection for adults (including guardianship, curators and safeguarding of justice)
• Control:
  • Medical conditions that may interfere with immune system testing: active cancer, active autoimmune disease, inflammatory conditions, immunosuppressive therapy. ; \* Pregnant or breastfeeding women ;
  • Patient's refusal ;
  • Person benefiting from a system of protection for adults (including guardianship, curators and safeguarding of justice)

• Patients:
  • Patient over 18 years of age with a myelodysplastic syndrome (WHO 2016 classification) of low risk (LR=IPSS-R\<4.5) or high risk (HR=IPSS-R\>4.5);
  • Patient naïve to specific treatment of MDS;
  • Patient who expressed no opposition to participating in the study. ;
  • Patient affiliated with the social security system.
• Control:
  • over 18 years of age,
  • Sample from blood donation (regardless of age) Or Patient \>60 years old, see at the geriatrics platform of the hospital la Grave (CHU of Toulouse),
  • having expressed his non opposition to participate in the study